Publication

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Authors not recorded

J Clin Oncol2009PMID 19075254stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (21)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 21

cancerChronic Myeloid Leukemia, BCR-ABL1 Positivecivic_curation1.00
drugDasatinibcivic_curation1.00
drugImatinibcivic_curation1.00
drugNilotinibcivic_curation1.00
geneABL1civic_curation1.00
variantABL1 D276Gcivic_curation1.00
variantABL1 E255Kcivic_curation1.00
variantABL1 E255Vcivic_curation1.00
variantABL1 F317Lcivic_curation1.00
variantABL1 F359Vcivic_curation1.00
variantABL1 F486Scivic_curation1.00
variantABL1 Fusioncivic_curation1.00
variantABL1 G250Ecivic_curation1.00
variantABL1 G398Rcivic_curation1.00
variantABL1 H396Rcivic_curation1.00
variantABL1 L248Vcivic_curation1.00
variantABL1 M351Tcivic_curation1.00
variantABL1 Q252Hcivic_curation1.00
variantABL1 T315Icivic_curation1.00
variantABL1 V299Lcivic_curation1.00
variantABL1 Y253Fcivic_curation1.00

Curated evidence

Evidence citing this paper (52)

50 items per page.

civicCuratedShowing 1–50 of 52 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 T315I + ABL1 Fusion4
Dasatinib	Acute Lymphoblastic Leukemia	Predictive	D	Supports Resistance	2	submitted	EID4377 In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 1… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4361 In an in vitro study, a Ba/F3 murine cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	4	accepted	EID2667 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	4	accepted	EID2670 In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 39.41-fold… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 BCR::ABL F317L1
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	—	rejected	EID2678 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 BCR::ABL M244V1
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	—	rejected	EID2637 In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 F486Y1
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	—	submitted	EID4570 In an in vitro study, a Ba/F3 murine cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 D276G + ABL1 Fusion4
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4356 In an in vitro study, a Ba/F3 murine cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4358 In an in vitro study, a Ba/F3 cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 2.63nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2663 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID2666 In an in vitro study, a Ba/F3 cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 E255K + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4346 In an in vitro study, a Ba/F3 murine cell line stably expressing the E255K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	accepted	EID2659 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2662 In an in vitro study, Ba/F3 cell line stably expressing the E255K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 6.69-fold), a… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 E255V + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4445 In an in vitro study, a Ba/F3 murine cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4451 In an in vitro study, a Ba/F3 cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 6.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	accepted	EID2850 In an in vitro study, a Ba/F3 cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 E279K + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4542 In an in vitro study, a Ba/F3 murine cell line stably expressing the E279K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 39.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4544 In an in vitro study, Ba/F3 cell line stably expressing the E279K mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to dasatinib treatment (IC50: 3nM vs. IC50: 1… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 F317L + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4380 In an in vitro study, a Ba/F3 murine cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4383 In an in vitro study, a Ba/F3 cell line stably expressing the F317L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 8… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2674 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 F359V + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID3814 In an in vitro study, a Ba/F3 murine cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 38.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2167 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	accepted	EID2170 In an in vitro study, a Ba/F3 cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold)… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 F486S + ABL1 Fusion2
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4439 In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 5.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2829 In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold)… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 G250E + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4312 In an in vitro study, a Ba/F3 murine cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	accepted	EID2645 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2648 In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold),… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 G398R + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4560 In an in vitro study, a Ba/F3 murine cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 48.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4561 In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2864 In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), c… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 H396P + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4555 In an in vitro study, a Ba/F3 murine cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4557 In an in vitro study, a Ba/F3 cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.95nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 H396R + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4409 In an in vitro study, a Ba/F3 murine cell line stably expressing the H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 33.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2687 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 L248V + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID4309 In an in vitro study, a Ba/F3 murine cell line stably expressing the L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID2641 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 L384M + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4526 In an in vitro study, a Ba/F3 murine cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with increased sensitivity to bosutinib treatment (… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4528 In an in vitro study, Ba/F3 cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 4.04 … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 M351T + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4392 In an in vitro study, a Ba/F3 murine cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2682 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2685 In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), com… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 Q252H + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4325 In an in vitro study, a Ba/F3 murine cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 33.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4326 In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2650 A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 V299L + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4539 In an in vitro study, a Ba/F3 murine cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2862 In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold)… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
ABL1 Y253F + ABL1 Fusion1
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID4339 In an in vitro study, a Ba/F3 murine cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 40n… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic